Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion.
Lipsic
Erik
E
Department of Clinical Pharmacology, Groningen University Institute for Drug Exploration, The Netherlands. e.lipsic@med.rug.nl
van der Meer
Peter
P
Henning
Robert H
RH
Suurmeijer
Albert J H
AJ
Boddeus
Kristien M
KM
van Veldhuisen
Dirk J
DJ
van Gilst
Wiek H
WH
Schoemaker
Regien G
RG
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects
D002316:Cardiotonic Agents; D019394:Ki-67 Antigen; D004921:Erythropoietin